Chronic graft-versus-host disease (GVHD) is an important complication of bone marrow transplantation. W e analyzed risk factors for chronic GVHD in 2,534 recipients of HLA-identical sibling transplants surviving at least 90 days after transplantation. The actuarial probability of developing chronic GVHD within three years posttransplant was 46% T 3% (95% confidence interval). The most important risk factor for chronic GVHD was acute GVHD. The 3-year probabilities of chronic GVHD were 28% k 3%. 49% k 5%. 59% T 6%. 80% t 9%. and 85% T 15% for persons with grades 0, 1, II, 111, and IV acute GVHD, respectively ( P < .OOOl). Among patients with no or grade I acute HRONIC graft-versus-host disease (GVHD) is an im-
p l a n t~.~ Most cases develop between 90 and 120 days posttran~plant.'.~ Chronic GVHD is characterized by fibrosis of the skin and sicca syndrome involving eyes and mouth.'-3 Hepatic abnormalities are common; other organs affected include the esophagus, small and large intestine, lungs, vagina, muscle, tendons, immune system, and bone marChronic GVHD causes both morbidity and mortality and is a leading cause of treatment failure after 1 year posttransplantation for severe aplastic anemia. 5 The relationship between chronic and acute GVHD is complex and incompletely understood. Several clinical features distinguish the two syndromes, including different times of onset and distinct patterns of organ involvement. There are less data regarding underlying pathologic or immunologic processes. Some data suggest that chronic GVHD is an extension of acute GVHD6; other data suggest that it is a distinct Several clinical features of chronic GVHD resemble those of autoimmune disorders such as scleroderma.'0," Therefore, it has been hypothesized that chronic GVHD represents a disease of immune dysregulation, an autoimmune disease occurring within an allogeneic setting. In contrast, acute GVHD is generally regarded as an alloimmune disorder caused by recognition of host genetic disparity by donor immune ~eIls.~-'* Because chronic GVHD is an important clinical problem after bone marrow transplantation, and because understanding its relationship to acute GVHD may be important for improved prevention and management, we analyzed risk factors for chronic GVHD in 2,534 recipients of HLAidentical sibling marrow transplants. Of particular interest were 217 patients with de novo chronic GVHD, in whom clinically evident acute GVHD did not occur. These patients enabled us to identify factors associated with risk of chronic GVHD independent of an association with clinically apparent acute GVHD.
GVHD, recipient age greater than 20 years, use of non-Tcell depleted bone marrow, and alloimmune female donors for male recipients predicted a higher risk of chronic GVHD. When all three adverse risk factors were present, the probability of chronic GVHD was 62% among persons with no prior acute GVHD and 85% among those with grade I acute GVHD. Among patients with grade II through IV acute GVHD, no other risk factor predicted chronic GVHD. These data identify individuals who might benefit from treatment strategies aimed at changing the incidence of chronic GVHD. 0 1990 by The American Society of Hematology.
MATERIALS AND METHODS
The study population was selected from 3,972 patients transplanted between January 1, 1982 Table 1 .
Acute GVHD was classified as absent (grade 0), mild (grade I), moderate (grade 11), moderately severe (grade 111), or severe (grade IV) using published criteria." Diagnosis of chronic GVHD was based on published criteria.'. ' Maximum overall severity of chronic GVHD was scored as absent, mild, moderate, or severe based on severity of skin and other organ involvement according to clinical judgement of the transplanter. Concordance rates among transplanters for diagnosis and grading of GVHD have been evaluated by the IBMTR in two previous studies and are moderate to high for patients with the most common manifestations of GVHD.I4," Actuarial probability of chronic GVHD was calculated using standard life-table methods. Life-table curves were ended when fewer than three patients remained at risk of chronic GVHD. The variables in Table 1 were exained for their association with chronic GVHD for patients with grade 0, I, 11, and 111-IV acute GVHD separately. bivariate analyses were done using the Lee-Desu statistic.I6 Factors associated with the risk of chronic GVHD in univariate analysis with P c .IO were examined in multivariate analysis using proportional hazards regression with a forward stepwise approach." Variables that improved the regression models with P i .OS were included in the final model. Relative risks of chronic GVHD associated with each variable were derived from multivariate analysis and adjusted for the effect of all other significant variables. The probabilities of chronic GVHD for patients with and without particular risk factors were derived from the multivariate regression model. All P values are two-tailed and, unless otherwise specified, based on the results of multivariate analysis. Because multiple comparisons were made, only P values i . 0 1 were considered statistically significant.
Diagnosis of GVHD.
Statistical analysis.
RESULTS

Acute GVHD.
There is high concordance for acute and chronic GVHD.'* Therefore, we first analyzed the incidence of acute GVHD in the study cohort (Table 2 ). Acute GVHD of grade I1 or greater severity occurred in 33% of the 2,534 persons in this study; 20% had grade 11,876 grade 111, and 5% grade IV. These incidence rates, lower than in an earlier IBMTR report,'' reflect censoring of persons dying with acute GVHD before day 90 and inclusion of patients who received T-cell-depleted grafts. These reasons also account for the lower proportion of cases with severe acute GVHD.
Of persons surviving 2 9 0 days, 66% developed no (40%) or grade I (26%) acute GVHD. We analyzed these populations separately since we were uncertain of the potential impact of grade I acute GVHD on the risk of chronic GVHD. Chronic GVHD developed in 38% (955 of 2,534) of patients at risk (Table 2) . Seventy-seven percent of cases had prior grade I to IV acute GVHD; 23% had no prior acute GVHD. The actuarial probability of having developed chronic GVHD by 3 years posttransplant was 46% f 3% (95% confidence interval, Fig 1) . The median time to onset of chronic GVHD was 11 1 days. In 48% of cases, chronic GVHD was scored as mild, in 37% as moderate, and in 15% as severe. Two hundred seventeen patients developed de novo chronic GVHD (9%), 738 (29%) had both acute and Chronic CVHD. For Chronic GVHD Acute and chronic GVHD chronic GVHD, and 768 (30%) had acute GVHD but did not subsequently develop chronic GVHD ( Table 2) . The strongest predictor of chronic GVHD was the incidence and severity of acute GVHD (Fig 1) . The probabilities of chronic GVHD by 3-years posttransplant in persons with grade 0, I, 11, 111, and IV acute GVHD were 28% k 3%, 49% 5%, 59% 6%, 80% k 9%, and 85% k 15%, respectively (univariate IP < .0001). Despite the strong correlation between severe acute GVHD and subsequent chronic GVHD, 35 patients who developed grade I11 to IV acute GVHD and survived for 6 or more months posttransplant did not develop chronic GVHD. No distinguishing features of this group could be identified.
Acute GVHD is such a powerful determinant of subsequent chronic GVHD that it might Relationship between acute and chronic GVHD.
De novo chronic GVHD. mask other factors affecting the risk. As a consequence, examining risk factors for chronic GVHD might simply represent an analysis of risk factors for acute GVHD. Therefore, we analyzed risk factors for chronic GVHD in 1,028 persons in whom acute GVHD was reportedly absent and in 666 persons with grade I acute GVHD (Table 3) . Multivariate analyses in these two cohorts showed three factors that correlated with the subsequent development of chronic GVHD: recipient age greater than 20 years (P < .0001), use of non-T-cell depleted marrow (P < .0001), and use of alloimmune female donors for male recipients (P < .002). Alloimmune female donors did not significantly increase the risk of chronic GVHD in female recipients. Relative risks are indicated in Table 3 . Patients with no prior acute GVHD and without any of the adverse risk factors had a probability of developing chronic GVHD of 10% versus 62% (P < .0001) in those with all three risk factors (Fig 2) . In those with grade I acute GVHD (Table 3) , the respective probabilities were 21% and 85% (P < .0001, Fig 2) .
None of these variables were significantly associated with the risk of chronic GVHD among persons with grade I1 or greater acute GVHD.
None of the other variables listed in Table 1 were associated with development of chronic GVHD after stratification for severity of acute GVHD. Specifically, neither clinical or subclinical cytomegalovirus (CMV) infection, CMV serologic status of donor or recipient pretransplant, recipient sex, race, pretransplant infection, laminar air flow isolation, nucleated marrow cell dose, nor the drug used to prevent GVHD were associated with the risk of chronic GVHD.
Other risk factors for chronic GVHD.
DISCUSSION
This study had two objectives: to identify risk factors for chronic GVHD and to investigate the relationship between acute and chronic GVHD. Risk factors for chronic GVHD. The strongest predictor of chronic G V H D was prior acute GVHD. The risk of chronic G V H D increased progressively with increasing severity of acute GVHD, such that more than 80% of patients who survive severe (grades 111 to IV) acute G V H D might be expected to develop chronic GVHD. Even patients with only mild (grade I) acute G V H D had a significantly increased risk of chronic G V H D as compared with patients considered to have no acute G V H D (49% versus 28%, univariate P < .OOOl).
MONTHS
Previous reports of factors associated with chronic G V H D rarely distinguished in detail between patients with or without prior acute GVHD. Although multivariate techniques were sometimes used to adjust for the effect of acute GVHD, since some variables have predictive value for persons without acute G V H D but not for those with acute GVHD (ie, interaction), this type of adjustment may not be sufficient to avoid confounding by the dominant effect of acute GVHD. This study is the first to examine closely factors predicting development of de novo chronic GVHD; these factors were related to the recipient, source, and characteristics of donor bone marrow. They included increasing recipient age, non-T-cell depleted transplants and alloimmune female donors for male recipients. It should be noted that while recipient age was more significant than donor age in multivariate analysis, these two variables were highly correlated ( r = .85), and it is difficult to be certain which one is biologically more important. Of interest, alloimmune female donors did not increase the risk of chronic GVHD in female recipients, suggesting that sensitization to H-Y antigens may increase the risk of chronic GVHD. These same three factors predicted chronic GVHD in patients with mild acute GVHD. No variable examined (Table 1) had predictive value in the group of patients with grades I1 to IV acute GVHD, in whom the development of acute GVHD appeared to be the dominant factor.
The strong association of acute and chronic G V H D is described by others,'.'" although increased risk with mild (grade I) acute G V H D is not previously reported. Previous studies also support an association of either donor'* or recipient5 age with chronic GVHD; the difficulty in dissociating the effects of these is discussed above. Several previous reports suggest a correlation between CMV infection and the development of chronic GVHD.".'' In this study, CMV infection was not associated with an increased risk of developing chronic GVHD. Furthermore, no effect on the development of chronic G V H D was associated with the CMV serological status of the donor, nor with the presence of clinical or subclinical CMV infection in the recipient pretransplant.
In addition to identifying patients with increased risk of chronic GVHD, we hoped to be able to provide insight into the relationship between acute and chronic G V H D by identifying differences in risk factors for the two diseases. For personal use only. on October 23, 2017. by guest www.bloodjournal.org From GVHD are different forms of the same disorder; and, (3) acute and chronic GVHD are distinct diseases with similar risk factors.
The first hypothesis is unlikely to be true since chronic GVHD occurred in 217 individuals with no antecedent acute GVHD. It is not possible to distinguish between the last two hypotheses with complete certainty, but the available evidence is most consistent with the notion that the two disorders have similar etiologies. Acute GVHD after HLAidentical sibling transplants is due to reaction of donor T cells against host minor histocompatibility antigens (reviewed in references 23 and 24); removing T cells from the donor bone marrow can prevent acute GVHD.25, 26 The fact that T-cell depletion also decreases the incidence of chronic GVHD suggests that alloreactive T cells are also important in its pathogenesis, although it is possible that two discrete effector cell types are removed during T-cell depletion. The fact that alloimmunization (generally by prior pregnancy) of female donors increases the risk of acute and chronic GVHD also suggests that alloreactivity is important for both acute and chronic GVHD. The continuing presence of proliferative or cytotoxic T cells with anti-host specificity is documented in mice,27 dogs,28 and humans2' with acute GVHD, and in dogs" and humans' with chronic GVHD, supporting the role of anti-host alloreactive responses in both acute and chronic GVHD.
Why then do some patients develop chronic but not acute GVHD? Immune interventions to prevent or treat GVHD may be more effective in suppressing acute rather than chronic manifestations of GVHD.30 In addition, drugs to prevent GVHD are generally given only in the early posttransplant period. Chronic GVHD frequently appears a t the time of cessation of methotrexate or tapering cyclosporine doses, and exacerbation of chronic GVHD on cessation of prednisone treatment is described." The fact that some patients with acute GVHD, especially mild acute GVHD, do not develop chronic GVHD may be explained by development in some patients of T cells specifically suppressive of antirecipient all~reactivity,~~ while those with chronic GVHD develop nonspecific suppressor cells.' Thus different development of different regulatory T cell subsets posttransplant may influence the clinical manifestations of the alloreactive component of GVHD.
Evidence favoring distinct mechanisms of acute and chronic GVHD includes the difference in clinical manifestations. Chronic GVHD resembles connective tissue disorders characterized by autoimmune reaction^.'.^ Circulating autoantibodies are found in patients with chronic GVHD." Autoreactive T cells are demonstrated in chronic but not acute GVHD in mice.33 These differences may be due to slow ontogeny of B and T cells after allogeneic marrow transplant^^^; the apparent absence of an autoimmune component in acute GVHD may simply be due to duration of time required to allow development of the cell populations responsible for these reactions.
A hypothesis unifying these diverse observations may be that acute and chronic GVHD have the same etiology (alloreactive T cells in the donor marrow) and thus share risk factors for the clinical manifestations of these T cells. Whether or not manifestations of acute GVHD are evident may be influenced by method and duration of GVHD prophylaxis and number of T cells i n f~s e d .~~.~~ The occurrence of chronic GVHD may depend on time, decrease in immune suppressive medications, and development of nonspecific suppressor and autoreactive T-cells. In summary, these data identify risk factors for developing chronic GVHD. They also suggest a close relationship between acute and chronic GVHD, and are consistent with the notion that these diseases may be causally related.
